PDL2 compounds
AssigneeIO Biotech ApS
InventorMads Hald Andersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.
Claims18
A vaccine composition comprising
- a peptide, or a pharmaceutically acceptable salt thereof, wherein the peptide is an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO:
- 1, and consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO:
- 1, comprises an amino acid sequence selected from SEQ ID NOs:
- 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO:
- 1;
- and
- an adjuvant.
A vaccine composition comprising a nucleic acid encoding an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO:
- 1;
- and a pharmaceutically acceptable additive, wherein the immunogenic peptide fragment consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO:
- 1, comprises an amino acid sequence selected from SEQ ID NOs:
- 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO:
- 1.
A nucleic acid encoding an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO:
- 1, wherein the immunogenic peptide fragment consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO:
- 1, comprises an amino acid sequence selected from SEQ ID NOs:
- 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.